These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 19666643)

  • 1. Effects of angiotensin receptor blockade on serial P-wave signal-averaged electrocardiograms after electrical cardioversion of persistent atrial fibrillation.
    Hegbom F; Tveit A; Grundvold I; Arnesen H; Smith P
    Europace; 2009 Oct; 11(10):1301-7. PubMed ID: 19666643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrillatory rate response to candesartan in persistent atrial fibrillation.
    Bollmann A; Tveit A; Husser D; Stridh M; Sörnmo L; Smith P; Olsson SB
    Europace; 2008 Oct; 10(10):1138-44. PubMed ID: 18664477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candesartan in the prevention of relapsing atrial fibrillation.
    Tveit A; Grundvold I; Olufsen M; Seljeflot I; Abdelnoor M; Arnesen H; Smith P
    Int J Cardiol; 2007 Aug; 120(1):85-91. PubMed ID: 17113170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-arginine, asymmetric dimethylarginine and rhythm outcome after electrical cardioversion for atrial fibrillation.
    Tveit A; Arnesen H; Smith P; Bratseth V; Seljeflot I
    Cardiology; 2010; 117(3):176-80. PubMed ID: 21063118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The prediction of atrial fibrillation recurrence after electrical cardioversion with P wave signal averaged EKG].
    Budeus M; Hennersdorf M; Perings C; Strauer BE
    Z Kardiol; 2004 Jun; 93(6):474-8. PubMed ID: 15252741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation.
    Tveit A; Seljeflot I; Grundvold I; Abdelnoor M; Smith P; Arnesen H
    Am J Cardiol; 2007 Jun; 99(11):1544-8. PubMed ID: 17531578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II blockade, YKL-40 and maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation.
    Tveit A; Seljeflot I; Smith P; Arnesen H; Svendsen JH
    Immunobiology; 2013 Oct; 218(10):1256-60. PubMed ID: 23731775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome after cardioversion of atrial fibrillation: prediction of recurrence with P wave signal averaged ECG and chemoreflexsensitivity.
    Budeus M; Wieneke H; Sack S; Erbel R; Perings C
    Int J Cardiol; 2006 Oct; 112(3):308-15. PubMed ID: 16309759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of atrial fibrillation in patients with cardiac dysfunctions: P wave signal-averaged ECG and chemoreflexsensitivity in atrial fibrillation.
    Budeus M; Hennersdorf M; Felix O; Reimert K; Perings C; Wieneke H; Erbel R; Sack S
    Europace; 2007 Aug; 9(8):601-7. PubMed ID: 17507361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candesartan, NT-proBNP and recurrence of atrial fibrillation after electrical cardioversion.
    Tveit A; Seljeflot I; Grundvold I; Abdelnoor M; Arnesen H; Smith P
    Int J Cardiol; 2009 Jan; 131(2):234-9. PubMed ID: 18201783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of serial P wave signal-averaged electrocardiograms following external electrical cardioversion for persistent atrial fibrillation: a prospective study.
    Guo XH; Gallagher MM; Poloniecki J; Yi G; Camm AJ
    Pacing Clin Electrophysiol; 2003 Jan; 26(1P2):299-304. PubMed ID: 12687833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spectral turbulence analysis of the signal-averaged electrocardiogram of the atrial activation as predictor of recurrence of idiopathic and persistent atrial fibrillation.
    Benchimol Barbosa PR; de Souza Bomfim A; Barbosa EC; Ginefra P; Helena Cardoso Boghossian S; Destro C; Nadal J
    Int J Cardiol; 2006 Mar; 107(3):307-16. PubMed ID: 15919123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of the efficacy of pulmonary vein isolation for the treatment of atrial fibrillation by the signal-averaged P-wave duration.
    Okumura Y; Watanabe I; Ohkubo K; Ashino S; Kofune M; Hashimoto K; Shindo A; Sugimura H; Nakai T; Kasamaki Y; Saito S
    Pacing Clin Electrophysiol; 2007 Mar; 30(3):304-13. PubMed ID: 17367349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amiodarone prophylaxis for atrial fibrillation of high-risk patients after coronary bypass grafting: a prospective, double-blinded, placebo-controlled, randomized study.
    Budeus M; Hennersdorf M; Perings S; Röhlen S; Schnitzler S; Felix O; Reimert K; Feindt P; Gams E; Lehmann N; Wieneke H; Sack S; Erbel R; Perings C
    Eur Heart J; 2006 Jul; 27(13):1584-91. PubMed ID: 16760210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of atrial remodeling after cardioversion of persistent atrial fibrillation measured with magnetocardiography.
    Lehto M; Jurkko R; Parikka H; Mäntynen V; Väänänen H; Montonen J; Voipio-Pulkki LM; Toivonen L; Laine M
    Pacing Clin Electrophysiol; 2009 Feb; 32(2):217-23. PubMed ID: 19170911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type III procollagen-N-peptide as a predictor of persistent atrial fibrillation recurrence after cardioversion.
    Kawamura M; Munetsugu Y; Kawasaki S; Onishi K; Onuma Y; Kikuchi M; Tanno K; Kobayashi Y
    Europace; 2012 Dec; 14(12):1719-25. PubMed ID: 22622138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Sensitivity Troponin I and Rhythm Outcome after Electrical Cardioversion for Persistent Atrial Fibrillation.
    Horjen AW; Ulimoen SR; Seljeflot I; Smith P; Arnesen H; Norseth J; Tveit A
    Cardiology; 2016; 133(4):233-8. PubMed ID: 26697854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of the recurrence of atrial fibrillation after successful cardioversion with P wave signal-averaged ECG.
    Budeus M; Hennersdorf M; Perings C; Wieneke H; Erbel R; Sack S
    Ann Noninvasive Electrocardiol; 2005 Oct; 10(4):414-9. PubMed ID: 16255751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.
    Ducharme A; Swedberg K; Pfeffer MA; Cohen-Solal A; Granger CB; Maggioni AP; Michelson EL; McMurray JJ; Olsson L; Rouleau JL; Young JB; Yusuf S
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preventive strategy for atrial fibrillation in arterial hypertension].
    Akhmedov VA; Dolgikh VT; Naumov DV; Dvornikov VE
    Klin Med (Mosk); 2009; 87(10):17-9. PubMed ID: 20017344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.